BioCryst Pharmaceuticals, Inc. (BCRX) News
Filter BCRX News Items
BCRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BCRX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BCRX News From Around the Web
Below are the latest news stories about BIOCRYST PHARMACEUTICALS INC that investors may wish to consider to help them evaluate BCRX as an investment opportunity.
Exploring High Growth Tech Stocks In January 2025The United States market has remained flat over the past week but has shown a robust 23% increase over the past year, with earnings projected to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions. |
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)—ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025— —Company achieved operating profit in 2024 (not including stock-based compensation) and expects to approach quarterly EPS profitability/positive cash flow in 2H 2025— —New drug application planned in 2025 for ORLADEYO granules in children up to age 12; will address significant unmet need— —Pipeline advancing into patients with Netherton syn |
BioCryst to Present at 43rd Annual J.P. Morgan Healthcare ConferenceRESEARCH TRIANGLE PARK, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025, at 6:00 p.m. ET. Link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com. About BioCryst PharmaceuticalsBioCryst Pharmaceuticals is a global biotec |
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 52,750 shares, and restricted stock units (RSUs) covering an aggregate of 36,975 shares, of BioCryst common stock. The options and RSUs were granted as of December 31, 2024, as inducements material to each employee entering into emplo |
The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose... |
High Growth Tech Stocks To Watch In December 2024Over the last 7 days, the U.S. market has risen 1.1%, and over the past 12 months, it is up by an impressive 32%, with earnings forecasted to grow by 16% annually. In this environment of robust growth, identifying high-growth tech stocks involves looking for companies that are well-positioned to capitalize on technological advancements and expanding market opportunities. |
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near FutureBioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) is possibly approaching a major achievement in its business, so we would... |
BioCryst Launches ORLADEYO® (berotralstat) in IrelandRESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Health Services Executive (HSE) in Ireland has recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Ireland will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks. “The positiv |
BioCryst to Present at Upcoming Investor ConferencesRESEARCH TRIANGLE PARK, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: 2024 Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 5:00 a.m. ET.7th Annual Evercore HealthCONx Conference in Coral Gables on Wednesday, December 4, 2024, at 2:35 p.m. ET.Piper Sandler 36th Annual Healthcare Conference in New York on Thursday, December 5, 2024, at 8:30 a.m. ET. Lin |
BioCryst Announces Strong Q3 2024 Revenue GrowthBioCryst ( (BCRX) ) has issued an announcement. BioCryst Pharmaceuticals reported a strong Q3 2024 with ORLADEYO net revenue of $116.3 million, growing 35.7% year-over-year, and adjusted full-year revenue guidance to $430-$435 million. The company introduced additional revenue guidance of $443-$448 million including RAPIVAB and achieved a GAAP operating profit of $7.7 million. Advancements in their pipeline include BCX17725 for Netherton syndrome and avoralstat for DME, showcasing significant pr |